These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33191818)

  • 41. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.
    Yamada H; Tanaka A; Kusunose K; Amano R; Matsuhisa M; Daida H; Ito M; Tsutsui H; Nanasato M; Kamiya H; Bando YK; Odawara M; Yoshida H; Murohara T; Sata M; Node K;
    Cardiovasc Diabetol; 2017 May; 16(1):63. PubMed ID: 28490337
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of short-term treatment with sitagliptin or glibenclamide on daily glucose fluctuation in drug-naïve Japanese patients with type 2 diabetes mellitus.
    Suzuki R; Eiki JI; Moritoyo T; Furihata K; Wakana A; Ohta Y; Tokita S; Kadowaki T
    Diabetes Obes Metab; 2018 Sep; 20(9):2274-2281. PubMed ID: 29770541
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus.
    Sromova L; Busek P; Posova H; Potockova J; Skrha P; Andel M; Sedo A
    Diabetes Res Clin Pract; 2016 Aug; 118():183-92. PubMed ID: 27388675
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improvement of β-cell function ameliorated glycemic variability in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion or in combination with sitagliptin treatment: a randomized control trial.
    Yuan G; Hu H; Wang S; Yang Q; Yu S; Sun W; Qian W; Mao C; Zhou L; Chen D; Wang Z; Gong Q; Wang D
    Endocr J; 2015; 62(9):817-34. PubMed ID: 26194272
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).
    Gallwitz B
    Drugs Today (Barc); 2007 Nov; 43(11):801-14. PubMed ID: 18174966
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes.
    Yuan G; Jia J; Zhang C; Yu S; Dong S; Ye J; Zhu T; Tang B; Qian W; Wang D; Yang L; Zhou L; Mao C
    Endocr J; 2014; 61(5):513-21. PubMed ID: 24621778
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats.
    Karabulut S; Coskun ZM; Bolkent S
    Pharmacol Rep; 2015 Oct; 67(5):846-53. PubMed ID: 26398375
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.
    Liu X; Men P; Wang Y; Zhai S; Liu G
    Lipids Health Dis; 2016 Nov; 15(1):204. PubMed ID: 27881129
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Beneficial Effects of Vildagliptin on Metabolic Parameters in Patients with Type 2 Diabetes.
    Shimodaira M; Niwa T; Nakajima K; Kobayashi M
    Endocr Metab Immune Disord Drug Targets; 2015; 15(3):223-8. PubMed ID: 25809193
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Oral Dipeptidyl-Peptidase-4 Inhibitor Sitagliptin Increases Circulating Levels Of Stromal-Derived Factor-1 Alpha.
    Papazafiropoulou AK; Papanas N; Trikkalinou A; Fousteris E; Melidonis A
    Exp Clin Endocrinol Diabetes; 2018 Jun; 126(6):367-370. PubMed ID: 28931178
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
    Garg SK; Moser EG; Bode BW; Klaff LJ; Hiatt WR; Beatson C; Snell-Bergeon JK
    Endocr Pract; 2013; 19(1):19-28. PubMed ID: 23186950
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial.
    Mita T; Katakami N; Shiraiwa T; Yoshii H; Onuma T; Kuribayashi N; Osonoi T; Kaneto H; Kosugi K; Umayahara Y; Yamamoto T; Matsumoto K; Yokoyama H; Tsugawa M; Gosho M; Shimomura I; Watada H;
    Diabetes Care; 2016 Mar; 39(3):455-64. PubMed ID: 26822324
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is Uric Acid a Missing Link between Previous Gestational Diabetes Mellitus and the Development of Type 2 Diabetes at a Later Time of Life?
    Molęda P; Fronczyk A; Safranow K; Majkowska L
    PLoS One; 2016; 11(5):e0154921. PubMed ID: 27166795
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury.
    Reichetzeder C; von Websky K; Tsuprykov O; Mohagheghi Samarin A; Falke LG; Dwi Putra SE; Hasan AA; Antonenko V; Curato C; Rippmann J; Klein T; Hocher B
    Br J Pharmacol; 2017 Jul; 174(14):2273-2286. PubMed ID: 28423178
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    Drugs Today (Barc); 2007 Jan; 43(1):13-25. PubMed ID: 17315049
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sitagliptin Protects Cardiac Function by Reducing Nitroxidative Stress and Promoting Autophagy in Zucker Diabetic Fatty (ZDF) Rats.
    Zhou Y; Wang H; Man F; Guo Z; Xu J; Yan W; Li J; Pan Q; Wang W
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):541-552. PubMed ID: 30328028
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of dextromethorphan as add-on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: a randomized, placebo-controlled, double-blinded, multiple crossover, single-dose clinical trial.
    Marquard J; Stirban A; Schliess F; Sievers F; Welters A; Otter S; Fischer A; Wnendt S; Meissner T; Heise T; Lammert E
    Diabetes Obes Metab; 2016 Jan; 18(1):100-3. PubMed ID: 26362564
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of sitagliptin on plaque changes in coronary artery following acute coronary syndrome in diabetic patients: The ESPECIAL-ACS study.
    Kuramitsu S; Miyauchi K; Yokoi H; Suwa S; Nishizaki Y; Yokoyama T; Nojiri S; Iwabuchi M; Shirai S; Ando K; Okazaki S; Tamura H; Watada H; Daida H
    J Cardiol; 2017 Jan; 69(1):369-376. PubMed ID: 27641967
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of serum uric acid with different levels of glucose and related factors.
    Yuan HJ; Yang XG; Shi XY; Tian R; Zhao ZG
    Chin Med J (Engl); 2011 May; 124(10):1443-8. PubMed ID: 21740795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.